CGC 2017 MEETING

Monday

08:00 - 08:05
Welcoming and Opening Announcements
Alan Lennon, PathGroup 
CGC President-Elect and 2017 Scientific Committee Chair
 
08:05 - 08:15
CGC Updates and Initiatives
President's update
Gordana Raca, Children's Hospital Los Angeles 
CGC 2017 President
 
08:15 - 09:15: Showcase of Genomic Profiling
 
08:15 - 08:30
Clinical utility of integrated genomic profiling in pediatric leukemia
Fumin Lin, Children’s Hospital of Philadelphia
 
08:30 - 08:45
GENOMIC analysis of childhood high grade glial brain tumors
Linda Cooley, Children’s Mercy Hospital
 
08:45 - 09:00
Addition of chromosomal microarray and next generation sequencing to FISH and classical cytogenetics enhances genomic profiling of myeloid malignancies
Pranil Chandra, Pathgroup
 
09:00 - 09:15
Comparison of genomic coverage using Affymetrix OncoScan Array and Illumina TruSight Tumor 170 NGS Panel for Detection of Copy Number Abnormalities in Clinical GBM Specimens
Jennifer Hauenstein, Emory University Hospital
 
09:15 - 10:15: Keynote Address
Challenges to delivering on the promise of personalized medicine
Gordon Mills, University of Texas, MD Anderson Cancer Center 
 
10:15 - 10:30: Coffee/Tea Break
 
10:30 - 11:30: Informatics
 
10:30 - 11:10
Rapid and infinitely scalable fusion gene detection in the cloud
Scott Newman, St. Jude Children’s Research Hospital
 
11:10 - 11:30
Variant interptretation knowledgebases for clinical testing in oncology
Obi Griffith, Washington University School of Medicine
 
11:30 - 12:30: Vendor Showcase: Agilent
 
12:30 - 13:25: Lunch with Vendors and Poster Viewing
 
13:25 - 13:30: Vendor Drawing
 
13:30 - 14:30: Liquid Biopsy
 
13:30 - 13:45
Optimization of blood-based liquid biopsy assays for the rapid identification of 19 actionable RNA fusion variants in NSCLC
Kristin Alexander, Biodesix
 
13:45 - 14:00
Evaluating circulating tumor DNA from cerebrospinal fluid
Leo Ballester, Houston Methodist Hospital, MD Anderson Cancer Center
 
14:00 - 14:15
Circulating tumor DNA genotyping in endometrial cancer
Ana Bolivar, The University of Texas, MD Anderson Cancer Center
 
14:15 - 14:30
Evaluation of restriction enzymes for the analysis of circulating free DNA by droplet digital PCR
Amanda Weaver, Biodesix
 
14:30 - 15:15: Special Topics
 
14:30 - 14:45
Promoting genomic test utilization by implementing standardized testing pathways
Kate Kroeger, Seattle Cancer Care Alliance
 
14:45 - 15:00
A comprehensive genomic tool for combined interpretation and reporting of sequence variants and copy number changes assessed by different platforms
Rashmi Kanagal-Shamanna, The University of Texas, MD Anderson Cancer Center
15:00 - 15:15
Utility of a comprehensive targeted DNA/RNA panel (170 genes) on a next generation sequencing (NGS) platform in evaluation of malignancies
Ravindra Kolhe, Augusta University
 
15:15 - 15:55: Dessert / Poster Viewing and Voting / Break with Vendors
 
15:55 - 16:00: Case Challenge: Puzzles for Prizes
 
16:00 - 17:00: Vendor Showcase: Illumina
 
17:00 - 19:00: Opening Reception with Vendors
 
19:30: Optional Activities - See Meeting Registration for Sign-Up
 

Tuesday

07:55 - 08:00: Case Challenge: Puzzles for Prizes
 
08:00 - 09:30: Collaborations leading to Important Guidelines
 
08:00 - 08:30
Clinical implementation of the standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of AMP, ASCO and CAP
Marilyn Li, The Children’s Hospital of Philadelphia
 
08:30 - 09:00
Classifying and reporting acquired copy number variants (CNVs) and copy neutral loss of heterozygosity (CN-LOH) in neoplastic disorders: joint recommendations from the America College of Medical Genetics and Genomics (ACMG), and the Cancer Genomics Consortium (CGC)
Gordana Raca, Children's Hospital Los Angeles 
 
09:00 - 09:30
Molecular genetics of chronic myeloid neoplasms- the findings of the Association of Molecular Pathology Chronic Myeloid Neoplasms Working Group 
Annette Kim, Brigham and Women's Hospital
 
09:30 - 09:55: Break with Vendors / Poster Viewing and Voting
 
09:55 - 10:00: Vendor Drawing
 
10:00 - 11:00: Vendor Showcase: Affymetrix/Thermo Fisher
 
11:00 - 12:15: Updates from CGC Workgroups: Developing Practice Guidelines for the use of Genomic Testing in Hematologic Malignancies and Solid Tumors
 
11:00 - 11:15
Genomic copy number aberrations and copy neutral loss of heterozygosity evaluation in myeloid neoplasms: Evidence-based recommendations for clinical genetic testing from the Myeloid Malignancies Working Group of the Cancer Genomics Consortium
Jennelle Hodge, Indiana University
Gordana Raca, Children's Hospital Los Angeles
 
11:15 - 11:30
Clinical utility and recommended approach for cytogenomic microarray analysis of renal neoplasia
Yajuan Liu, University of Washington
 
11:30 - 11:45
CGC Working Group recommendations for CLL: utility of molecular technologies such as microarrays and NGS for routine diagnostic use
Patricia Miron, UMass Memorial Medical Center / Quest Diagnostics
 
11:45 - 12:00
Development of consensus recommendations for genomic testing of plasma cell neoplasms for diagnosis and prognosis
Trevor Pugh, Princess Margaret Cancer Center

 
12:00 - 12:15
Practice guidelines for genetic/genomic testing in pediatric B-lineage acute lymphoblastic leukemia (B-ALL): A Cancer Genomics Consortium (CGC) workgroup
Yassmine Akkari, Legacy Health
 
12:15 - 14:00: Break-Out Sessions with Lunch
 
14:00 - 15:00: Keynote Address
An Oncologist’s perspective of using multimodal genetic testing for treating/placing refractory patients on clinical trials
David Spigel, Sarah Cannon Research Institute
 
15:00 - 16:00: Assisting Interpretation
 
15:00 - 15:15
Copy number identification by Viterbi
Jason Powers, Q2 Solutions / EA Genomics
Chad Brown, Q2 Solutions / EA Genomics
 
15:15 - 15:30
Investigating structural variation using optical genome mapping technology
Ramakrishnan Rajagopalan, Drexel University
 
15:30 - 15:45
Assessment of breast cancer with borderline HER2 status using MIP microarray
Hui Chen, MD Anderson Cancer Center
 
15:45 - 16:00
EvaGreen-based droplet digital PCR: a rapid and inexpensive method to confirm and enhance breakpoint resolution of CNVs detected by CMA.
Hou-Sung Jung, Dartmouth-Hitchcock Medical Center
 
16:00 - 16:25: Coffee / Tea Break with Vendors and Poster Viewing/Voting
 
16:25 - 16:30: Case Challenge: Puzzles for Prizes
 
16:30 - 17:30: Interpretive Considerations: Clinical Experience and Accessing and Curating Information
 
16:30 - 17:00
Significance of copy-neutral loss of heterozygosity detected in oncology samples: Insights and mechanisms
Stuart Schwartz, Laboratory Corporation of America
 
17:00 - 17:15
A proactively developed and curated copy number/copy neutral loss of heterozygosity interpretation database/system across multiple neoplasms for highly informative and timely reporting in a high volume laboratory
Katie Olds, PathGroup
 
17:15 - 17:30
Introduction to publically available knowledgebases to aid interpretations of genomic findings in oncology
Beth Pitel, Mayo Clinic
 
17:30 - 19:00: Poster Session Viewing and Voting / Happy Hour with Vendors / Cash Bar
 
Dinner on Your Own
 

Wednesday

07:55 - 08:00: Case Challenge: Puzzles for Prizes
 
08:00 - 09:30: Special Topics
 
08:00 - 08:15
Comprehensive characterization of genomic, transcriptomic and epigenomic artifacts introduced in formalin-fixed, paraffin-embedded tissue
Erik Zmuda, Nationwide Children’s Hospital
 
08:15 - 08:30
Detection of gene fusions in pediatric hematologic malignancies and solid tumors with the OncoKids next generation sequencing based assay
Jackie Biegel, Children’s Hospital Los Angeles
 
08:30 - 08:45
TARGETED amplicon based next-generation sequencing facilitates detection of KMT2A/MLL gene copy number changes
Rashmi Kanagal-Shamanna, The University of Texas, MD Anderson Cancer Center
 
08:45 - 09:00
Targeted-capture sequencing of the immunoglobulin locus to detect V(D)J rearrangements and recurrent illegitimate translocations in multiple myeloma
Signy Chow, University of Toronto
 
09:00 - 09:15
Experimental validation of structural variation candidates by the FusorSV algorithm
Kritika Shankar, University of Connecticut
 
09:15 - 09:30
HD-SNP microarray analysis of the study 9 high risk ALL patients – increased yield of important prognostic information
Nadine Berry, Molecular Medicine, NSW Health Pathology
 
09:30 - 10:30: Keynote Address
The state of the art in genetic testing in acute lymphoblastic leukemia
Elizabeth Raetz, Huntsman Cancer Institute
 
10:30 - 10:35: Announcement of Poster Winners
 
10:35 - 10:55: Break with Vendors and Winning Poster Viewing
 
11:00 - 12:15: Special Considerations for Array Testing in CLL and MM
 
11:00 - 11:15
Comparison of FISH, CpG-stimulation, chromosomal microarray, and mate-pair sequencing in 20 patients with CLL or lymphoma
Stephanie Smoley, Mayo Clinic
 
11:15 - 11:30
Evaluation of multimodality cytogenetic testing in CLL to determine best testing strategy
Jing Li, Fred Hutchinson Cancer Center
 
11:30 - 11:45
CD138 enrichment strategy and results of chromosome genomic array testing (CGAT) for multiple myelomas
Lena Glaskova, Seattle Cancer Care Alliance
 
11:45 - 12:00
Utilization of a SNP microarray for chronic lymphocytic leukemia: Efficacy, informative findings and prognostic capabilities
Stuart Schwartz, Laboratory Corporation of America
 
12:00 - 12:15
Utilization of a SNP microarray for the study of multiple myeloma patients: novel findings and better stratification of patients
Savanna Schepis, Laboratory Corporation of America
 
12:15 - 12:45: CGC Business Meeting
Meet the Board
Closing Remarks and Commencement of Meeting
 

Comments are closed.